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-Reactive Protein
nd the Vascular Endothelium
mplications for Plaque Instability*
shwarlal Jialal, MD, PHD,
ridevi Devaraj, PHD,
ma Singh, PHD
acramento, California
-reactive protein (CRP), a member of the pentraxin
amily, is the prototypic marker of inflammation. Recently
ata have emerged to suggest that CRP is a risk marker for
ardiovascular disease and is additive to low-density li-
oprotein (LDL) cholesterol and the Framingham 10-year
isk score (FRS) (1). In this regard, the American Heart
ssociation and Centers for Disease Control and Preven-
ion have recommended that in patients with an FRS of
0% to 20%, a CRP between 3 and 10 mg/l confers a greater
isk of cardiovascular disease (2). Furthermore, Grundy et
l. (3) incorporated CRP 3 mg/l as part of the two risk
actors in moderately high-risk patients with an FRS of 10%
See page 1369
o 20% in whom a therapeutic option or an LDL cholesterol
oal of100 mg/dl should be offered. The CRP levels seem
o be a good metric of genetic and environmental factors
hat could predispose to cardiovascular disease. These in-
lude increased adiposity, smoking, metabolic syndrome,
iabetes, hypertension, chronic kidney disease, sleep apnea,
nd so on. Although previously it was believed that CRP
as produced exclusively by the liver, recent data suggest
hat CRP is also produced in human atheroma. Yasojima et
l. (4) provided cogent evidence showing that CRP mRNA
n atheroma were ten times greater than in the normal
essel. Other groups have confirmed that CRP messenger
ibonucleic acid is present in directed atherectomy samples
nd that smooth muscle cells and endothelial cells synthe-
ize and secrete CRP (5,6). The obvious question that arises
s whether CRP in the vessel wall can contribute to
therothrombosis and plaque instability.
The article by Montero et al. (7) in this issue of the
ournal shows that CRP increased levels of certain matrix
etalloproteinases (MMP-1 and -10) from human umbil-
cal vein endothelial cells (HUVECs) and human aortic
ndothelial cells (HAECs) without any significant change
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Laboratory for Atherosclerosis and Metabolic Research, University ofH
alifornia at Davis Medical Center, Sacramento, California. Supported by National
nstitutes of Health Grant RO1 HL074360, K24 AT00596.n the tissue inhibitor of MMP. They also showed that CRP
reatment resulted in an increase in MMP activity. Further-
ore, specific inhibition of p38 mitogen-activated protein
inase (MAPK) or MAPK-activated ERK kinase (MEK)
bolished the CRP induction of MMP-1, whereas blockade
f MMP-10 induction required the simultaneous blockade
f p38 MAPK and Jun N-terminal kinase (JNK) pathways.
n patients with CRP3 mg/l compared with patients with
ower levels of CRP, both MMP-1 and -10 levels were
levated after adjusting for confounding variables. Finally,
hey showed that CRP and MMP co-localize in the
ndothelial layer and macrophage-rich areas of advanced
therosclerotic plaques. These are important observations
hat support the contention that CRP is a marker of plaque
ctivity and can indeed participate in acute coronary syn-
romes (ACS). However, it is disappointing that the
nvestigators focused most of their findings in HUVEC
iven that aortic endothelial cells are the primary site of
therosclerosis. Their findings confirm those of a previous
roup that show that CRP increases production of MMP-1
n macrophages through the fragment of antibody with the
-terminal of immunoglobulin chain (Fc) gamma receptor
I, CD32, via ERK activation (8). Recently, it has been
hown in HAEC that CRP, via the Fc gamma receptors
D32 and CD64, mediates its biological effects (9). Thus,
n the present report, the investigators should have also
lucidated the receptor pathway because they show by
onfocal microscopy that CRP co-localizes with MMP in
he endothelial layer. The data with regard to elevated
MP-1 and -10 in patients with high CRP levels cannot
enote cause and effect. Previously, Lin et al. (10) showed
hat CRP induces MMP-2 and -9 activities in HUVEC.
hese collective findings suggest that CRP may promote
atrix degradation and thus contribute to plaque vulnera-
ility. The concept that CRP might participate in athero-
hrombosis is not new. Pasceri et al. (11) previously showed
n HUVEC and human coronary artery endothelial cell
HCAEC) that CRP up-regulated vascular cell adhesion
olecule (VCAM-1), intercellular adhesion molecule
ICAM-1), E-selectin, and monocyte chemotactic protein-1
MCP-1) and promoted increased monocyte adhesion. Two
aboratories independently reported that CRP decreased
ndothelial nitric oxide synthase (eNOS) messenger ribo-
ucleic acid, protein, and activity in aortic and saphenous
ein endothelial cells (6). Also, CRP has been shown to
nhibit prostacyclin in HAEC via nitration of prostacyclin
ynthase (6). Other studies that support a role for CRP in
therothrombosis include up-regulation of tissue factor
rocoagulant activity in monocytes, increased plasminogen
ctivator inhibitor-1 (PAI-1) activity, and inhibition of
issue plasminogen activator (tPA) antigen and activity in
AEC (6,12). C-reactive protein stimulates PAI-1 via up-
egulation of Rho kinase (13) and inhibits tPA via up-
egulation of interleukin (IL)-1 and tumor necrosis factor in
AEC (12). Patients with high CRP compared with those
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Editorial Comment April 4, 2006:1379–81ith low CRP had a prolonged euglobin clot lysis time (12),
upporting the data in the human CRP transgenic mice
howing a higher frequency of arterial thrombosis of the
ransgenic mice compared with wild-type mice after femoral
njury (14).
Thus, CRP has numerous effects on endothelial cells that
ould support a pro-inflammatory, pro-thrombotic role
Fig. 1). Its procoagulant effects include inhibition of
NOS, prostacyclin, tPA and up-regulation of PAI-1, and
he proinflammatory effects include up-regulation of IL-6,
dhesion molecules, ICAM and VCAM, and the chemo-
ines, MCP-1 and IL-8. It is also important to note here
hat the effects of CRP on eNOS, prostacyclin, tPA, PAI-1,
nd IL-8 have been shown to be independent of endotoxin
nd azide contamination as reported also by Montero et al.
7,12,13). Furthermore, in addition to stimulating tissue
actor in macrophages, CRP has been shown to promote the
ptake of oxidized LDL, which would be relevant to the
igure 1. Effects of C-reactive protein (CRP) on the vascular endothelium
c  fragment of antibody with the c-terminal of immunoglobulin cha
onocyte chemotactic protein-1; MMP-1  matrix metalloproteinase-1;
tumor necrosis factor; tPA  tissue plasminogen activator.enesis of the atherosclerotic lesion, including plaque insta- tility (6). The recent observations that CRP is produced in
ortic endothelial cells and that secreted CRP could be
ugmented 100-fold with human macrophage-conditioned
edia incubated with endothelial cells argues for paracrine
nd autocrine loops in the atheroma that could result in
xceedingly high CRP concentrations in microdomains (5).
ndeed, plasma CRP levels ranging from 20 to 64 mg/l have
een reported in patients with ACS (15,16), and levels seem
o be higher in aortic sinus samples and to predict poorer
utcomes (17–19).
In conclusion, data are emerging to support a role for
RP in atherothrombosis; CRP has been shown to induce
yocardial infraction in a rat coronary ligation model and
ncreased cerebral infarct size in rats after middle cerebral
rtery occlusion (20,21). Furthermore, CRP has been shown
o promote neointimal formation after balloon angioplasty
22). With regard to the data in mice, it is unclear how
ruitful this line of investigation would prove to be because
S  cell adhesion molecules; eNOS  endothelial nitric oxide synthase;
 interleukin; MAPK  mitogen-activated protein kinase; MCP 1 
b  nuclear factor kb; PAI-1  plasminogen activator inhibitor-1; TNF. CAM
in; ILhe major acute phase reactant in mice is not CRP, but
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April 4, 2006:1379–81 Editorial Commenterum amyloid A (SAA) and serum amyloid P component
SAP). Thus it is not surprising that the studies to date that
ave introduced human CRP into mice have yielded con-
icting results (23).
If CRP contributes to plaque instability and the genesis
f ACS, then modulating CRP in the setting of ACS may
rove beneficial. In this regard, exciting new data are
merging. In both Pravastatin or Atorvastatin Evaluation
nd Infection therapy (PROVE-IT) and the A to Z study
15,24), concomitant reduction of LDL and CRP with
tatin therapy resulted in a greater benefit in cardiovascular
nd points, further supporting the idea that CRP might be
n active participant in atherothrombosis and the genesis of
CS. However, these exciting preliminary findings need to
e confirmed in future studies.
eprint requests and correspondence: Dr. Ishwarlal Jialal, Lab-
ratory for Atherosclerosis and Metabolic Research, UC Davis
edical Center, Sacramento, California 95817. E-mail:
jialal@ucdavis.edu.
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